NCT07864532Completed
Prevalence and Determinants of Therapeutic Non-Compliance in Patients With Chronic Pathologies ( PDTNCCP)
Prevalence and Determinants of Therapeutic Non-compliance in Patients With Chronic Pathologies
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
Identify the prevalence and determinants related to therapeutic non adherence among patients with chronic pathologies and to design effective interventions optimizing treatment compliance.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 3000 (actual)
- First submitted
- 5 Apr 2024
- Start date
- 1 Mar 2024
- Primary completion date
- 31 May 2024
- Lead sponsor
- University of Monastir
- Diseases
- Heart failure, High blood pressure
- NCT number
- NCT07864532
What you commit to
- Study type: Observational
- Participants enrolled: 3000
- From 1 Mar 2024 to the primary completion date, 31 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients unable to understand spoken words, such as those with visual or hearing impairment.
Other
- Non-cooperative or non-consenting patients.
Who the study is looking for
- Patients with a history of arterial hypertension (HTA), diabetes, obstructive pulmonary disease (COPD), and heart failure (HF), isolated or combined.
- Patients who have been under treatment for more than 6 months.
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nouira Coordinator of this site? Confirm its status | Monastir | Tunisia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.